Varicella Live Vaccine Market Thumbnail Image

2019

Varicella Live Vaccine Market

Varicella Live Vaccine Market Size, Share, Competitive Landscape and Trend Analysis Report, by Product, Application and Provider : Global Opportunity Analysis and Industry Forecast, 2018-2026

LS : Healthcare

Select an option
Author's: Sanjivan Gill | Roshan Deshmukh
Publish Date:

Get Sample to Email

Varicella Live Vaccine Market Outlook-2026

The global varicella live vaccine market was valued at $2,714 million in 2018, and is expected to reach $4,222 million by 2026, registering a CAGR of 5.7% from 2019 to 2026.

Varicella zoster is also known as Human alphaherpesvirus 3 and causes chicken pox and herpes zoster in humans. The infection caused by this virus can be prevented by the use of vaccinations that are specially formulated to provide immunity against the virus. There are mainly two types of vaccinations available to provide immunity against varicella zoster such as monovalent varicella vaccine and combination varicella vaccine. These vaccines differ from each other on the basis of their contents. For instance, monovalent varicella vaccine contains only one strain of virus whereas the combination varicella vaccine contains more than one strain of virus and offers immunity against more than one virus.

Varicella Live Vaccine Market

Surge in immunization programs across the globe is the major factor that boosts the growth of the varicella live vaccine market. Furthermore, increase in awareness related to the use of varicella live vaccines and rise in adoption of varicella vaccination worldwide also fuel the varicella live vaccine market growth. However, high monetary inputs associated with the production of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.

VARICELLA LIVE VACCINE MARKET SEGMENTATION

The global varicella live vaccine market size is studied based on product, application, provider, and region. On the basis of product, the market is bifurcated into monovalent varicella vaccine and combination varicella vaccine. By application, it is divided into chicken pox immunization, herpes zoster immunization and measles, mumps, rubella, and varicella (MMRV) immunization. On the basis of provider, it is segmented into public provider and private provider. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, the UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and, rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Segment Review

Based on product, the monovalent varicella vaccine segment occupied the largest varicella live vaccine market share in 2018. Moreover, monovalent varicella vaccine segment is also expected to experience rapid growth during the forecast period as these vaccines exhibit lesser chances of inducing febrile seizures in children as compared to combination vaccines. Moreover, easy availability and presence of large number of products are the other factors that boost the varicella vaccine market growth.

Varicella Live Vaccine Market
By Product
Your browser does not support the canvas element.

Monovalent Varicella Vaccine segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Based on application, the varicella live vaccine market is classified into chicken pox immunization, herpes zoster immunization and measles, mumps, rubella, and varicella (MMRV) immunization. Chicken pox immunization acquired the largest varicella live vaccine market share owing to vaccination employed with an initial aim of building immunity against chicken pox. The herpes zoster segment is expected to experience rapid growth during the forecast period owing to surge in geriatric population worldwide and rise in awareness about the use of varicella live vaccines for herpes zoster.

Varicella Live Vaccine Market
By Application
Your browser does not support the canvas element.

Herpes zoster is projected as one of the most lucrative segment.

By region, North America accounted for the major share of the varicella live vaccine market in 2018 and is expected to continue this trend owing to easy availability of varicella live vaccines, presence of skilled healthcare experts, and presence of major key players that offer varicella live vaccines. Asia-Pacific is expected to grow at the fastest rate during the forecast period due to surge in awareness related to importance of immunization and rise in disposable income. The developing economies offer lucrative opportunities for varicella live vaccine providers to expand their business. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, Malaysia, and others.

Varicella Live Vaccine Market
By Region
2026
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 7.0% during 2019-2026.

The global varicella live vaccine market is highly competitive and the prominent players in the market have adopted various strategies for garnering maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Bio-Med Pvt. Limited, Changchun BCHT Biotechnology Co. Ltd., Emcure Pharmaceuticals Limited, GlaxoSmithKline plc, Green Cross Holdings (GC Pharma), Merck & Co. Inc., Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation), Novo Medi Sciences Pvt. Ltd., Sanofi, and Takeda Pharmaceutical Company Limited.

Key Benefits for Varicella Live Vaccine Market:

  • This report entails a detailed quantitative analysis along with the current global varicella live vaccine market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The varicella live vaccine market forecast is studied from 2019 to 2026. 
  • The market size and estimations are based on a comprehensive analysis of key developments in the varicella live vaccine industry. 
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Varicella Live Vaccine Market Report Highlights

Aspects Details
icon_5
By PRODUCT
  • Monovalent Varicella Vaccine
  • Combination Varicella Vaccine
icon_6
By APPLICATION
  • Chickenpox Immunization
  • Herpes Zoster Immunization
  • Mumps, measles, rubella & varicella (MMRV) Immunization
icon_7
By PROVIDER
  • Public
  • Private
icon_8
By Region
  • North America  (U.S, Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
icon_9
Key Market Players

CHANGCHUN BCHT BIOTECHNOLOGY CO. LTD, GLAXOSMITHKLINE PLC, MITSUBISHI CHEMICAL HOLDINGS CORPORATION (MITSUBISHI TANABE PHARMA CORPORATION), GREEN CROSS HOLDINGS (GC PHARMA), TAKEDA PHARMACEUTICAL COMPANY LIMITED, NOVO MEDI SCIENCES PVT. LTD, EMCURE PHARMACEUTICALS LIMITED (ZUVENTUS HEALTHCARE LTD.), SANOFI, BIO-MED PVT. LIMITED, MERCK & CO. INC

Analyst Review

Varicella live vaccines are expected to witness high adoption in the near future, owing to increase in number of immunization programs across the globe. In addition, the market is exhibiting high growth rate, owing to surge in awareness about use of the varicella live vaccine market. Moreover, rise in adoption of varicella live vaccines is another factor that fuels the growth of the market. Asia-Pacific and LAMEA are expected to offer lucrative growth opportunities to the key players. This is majorly attributed to factors such as improvement in healthcare facilities, rise in disposable income, and rapid improvement in economic conditions. However, high monetary inputs required for the production of these vaccines hinders the growth of the varicella live vaccine market. Varicella live vaccine manufacturers and distributors have focused on expanding their presence in the emerging economies to strengthen their foothold in the market.

North America garnered the largest share of this market due to rise in immunization programs, easy availability of varicella live vaccine products, and presence of skilled healthcare professionals.

Author Name(s) : Sanjivan Gill | Roshan Deshmukh
Frequently Asked Questions?

The total market value of varicella live vaccinedevice market is $2,713.52 million in 2018.

The forcast period for varicella live vaccinedevices market is 2019 to 2026

The market value of influenza vaccine market in 2019 is $2,871.99 million

The base year is 2018 in varicella live vaccinedevices market

Merck & Co. Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited., Green Cross Holdings (GC Pharma), and Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation), held a high market position in 2018.

Monovalent varicella vaccine segment is the most influencing segment growing in the varicella live vaccines market

The key trend in the varicella vaccine market is the surge in immunization programs across the globe is the major factor that drives the growth of the market.

Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China with a CAGR of 8.7%.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Varicella Live Vaccine Market

Global Opportunity Analysis and Industry Forecast, 2018-2026